Zynex Medical Holdings, Inc. (OTCBB: ZYNX), a provider of pain management systems and electrotherapy products for medical patients with functional disability, announces an increase in its orders of 245% for November of 2007 compared to the same month last year.
Thomas Sandgaard, CEO, said: "Even though we posted our second-best order intake so far, our production was slowed down by moving to new offices and not having enough products for our sales reps. The shorter month and the holidays also played a role and we hope to continue our growth in the coming months.”
Zynex received 1,260 orders in November 2007 versus 365 orders twelve months ago and 1,452 orders in October of 2007. Zynex has not yet finalized its results for the fourth quarter of 2007, including the impact of increased orders. Zynex will state these results in the Form 10-KSB for the 2007 full year.
About Zynex Medical Holdings, Inc.
Zynex Medical Holdings, Inc. (founded in 1996) engineers, manufactures, markets and sells its own design of electrotherapy medical devices in two distinct markets: standard digital electrotherapy products for pain relief and pain management; and the NeuroMoveTM for stroke and spinal cord injury (SCI) rehabilitation. Zynex's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain.
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, our dependence on third party manufacturers to produce our goods on time and to our specifications, the acceptance of our products by hospitals and clinicians, implementation of our sales strategy including a strong direct sales force and other risks described in our 10-KSB Report for the year ended December 31, 2006.
Zynex Medical Holdings, Inc.
Thomas Sandgaard, CEO, 303-703-4906
www.zynexmed.com